Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy
Authors:
- 14 January 2025
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Abstract
Purposes This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra. Methods Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra. Results The median follow-up period was 57 months (interquartile range, 30–85 months). The exact T stage of the patients with UC of the prostatic urethra was carcinoma in situ (CIS) in 29 (27 in the prostatic urethral mucosa and two in the ductal spread), Ta in 7, Ta + CIS in 2, and T1 in 1. All 39 patients had previous or concurrent bladder cancer. Patients with UC of the prostatic urethra experienced significantly higher rates of intravesical recurrence, progression (MIBC or metastasis), and subsequent radical cystectomy than those without UC of the prostatic urethra. In the multivariate analysis, UC of the prostatic urethra was a significant risk factor for progression (hazard ratio 4.06, 95% confidence interval 1.86–8.86, p < 0.001). Conclusions This study reported the largest number of clinical outcomes after BCG treatment in patients with UC of the prostatic urethra. Concomitant UC of the prostatic urethra is a strong predictor of subsequent progression; therefore, early timing of radical cystectomy should be discussed.Keywords
This publication has 18 references indexed in Scilit:
- Detection and Surveillance of Bladder Cancer Using Urine Tumor DNACancer Discovery, 2019
- The distribution of BCG prostatitis: A clue for pathogenetic processes?The Prostate, 2018
- A systematic review and meta‐analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimensBJU International, 2018
- Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical CystectomyBladder Cancer, 2017
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-GuérinEuropean Urology, 2012
- Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette‐Guérin immunotherapy?BJU International, 2009
- History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success StoryJournal of Urology, 2008
- Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significanceHuman Pathology, 2006
- Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases.2003